Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Equity-to-Asset : 0.82 (As of Mar. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Checkmate Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $55.00 Mil. Checkmate Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2022 was $66.94 Mil.

The historical rank and industry rank for Checkmate Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

CMPI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1 Med: 0.92 Max: 0.95
Current: 0.82

During the past 4 years, the highest Equity to Asset Ratio of Checkmate Pharmaceuticals was 0.95. The lowest was -0.10. And the median was 0.92.

CMPI's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs CMPI: 0.82

Checkmate Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Checkmate Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Equity-to-Asset Chart

Checkmate Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Equity-to-Asset

0.73

-0.10

0.94

0.88

Checkmate Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Equity-to-Asset	Get a 7-Day Free Trial									0.94	0.93	0.91	0.88	0.82

Competitive Comparison of Checkmate Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Checkmate Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Checkmate Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's Equity-to-Asset falls into.

Checkmate Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Checkmate Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )	=	Total Stockholders Equity	/	Total Assets
	=	69.459	/	78.838
	=

Checkmate Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2022 is calculated as

Equity to Asset (Q: Mar. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	55.002	/	66.944
	=

Checkmate Pharmaceuticals (NAS:CMPI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Checkmate Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142

Website

https://www.checkmatepharma.com

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Executives

Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash	director, officer: Chief Executive Officer	C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg	director, officer: Chief Scientific Officer	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski	officer: Chief Financial Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger	director, officer: President and CEO	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono	director	C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff	director	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan	officer: Chief Operating Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary	officer: Chief Business Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6